Phase 1a trial in 57 healthy adults: single-dose live oral cholera vaccine PanChol was well tolerated, and all 45 recipients of ≥10^5 CFU with samples seroconverted to both serotypes; diarrhoea was reported in 39% of vaccinees vs 38% with placebo.
RCTn = 57
Leitner et al. Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial